Why SARS-CoV-2 bounces back after antiviral treatment
The antiviral combination of nirmatrelvir and ritonavir (brand name Paxlovid) is an effective treatment for people with COVID ...
News Medical on MSN11d
In silico docking of clinically approved drugs against the SARS-CoV-2 receptor-binding domain
Announcing a new article publication for BIO Integration journal. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), first identified in China in December 2019, rapidly spread worldwide, ...
Pharmabiz2d
NanoViricides announces its antiviral drug, NV-387 can fight bird flu pandemic; H5N1 virus will not be able to escape even as it changes in the field
Shelton, Connecticut Thursday, February 13, 2025, 16:00 Hrs [IST] ...
Protection from COVID reinfections plummeted from 80% to 5% with omicron
With the rise of omicron came the fall of long-lasting protection from reinfection with the pandemic coronavirus SARS-CoV-2, ...
No, Moderna Did Not Create Its COVID Vaccine Two Years Before the Pandemic
An image that is spreading widely online claims that Moderna had created its COVID-19 vaccine two years before the pandemic ...
pulmonologyadvisor3d
COVID Antiviral, mAb Treatments Reduce Mortality and Hospitalization Rates
Certain antiviral and mAb therapies were shown to lower mortality and hospitalization rates in those infected with SARS-CoV-2 Omicron variants.
Underscoring the immense potential of chitosan in fighting a wide spectrum of viruses: A plausible molecule against SARS-CoV-2?
Chitosan, a naturally occurring polysaccharide derived from chitin, has demonstrated significant potential as an antiviral ...
Revive Therapeutics Announces Update on R&D Focus on Bucillamine for Infectious Diseases and Medical Countermeasures
The Company will be focusing on the following programs with Bucillamine: Revive is targeting nerve agent exposure as its initial indication for its medical countermeasures program. Nerve agents are ...